The ‘Campaign’ Girds for More Battles in the Tobacco Wars
January 1st 2001WASHINGTON-Since its inception 5 years ago, the Campaign for Tobacco-Free Kids has become a major force in the policy wars over tobacco. Media savvy and quick to respond to news opportunities, the Campaign has been effective in publicizing the deceptive practices of the tobacco industry, its political contributions at the state and national level, and its changing advertising practices aimed at enticing youngsters into smoking.
Exploring the Hidden Financial Burden of Cancer Therapy
January 1st 2001Approaches to cancer treatment have rapidly grown complex and costly, causing heightened awareness among patients, physicians, employers, and insurance providers. Annual costs for cancer are about $107 billion, accounting for 20% of all health care costs.[1]
Phase I Study of Irinotecan and Concurrent Radiation Therapy for Upper GI Tumors
Irinotecan (Camptosar) is an active chemotherapeutic agent for lung, gastric, esophageal, and colorectal cancers and a potent radiosensitizer. This phase I study was designed to assess the maximum tolerated dose of weekly
Thalidomide in Hematologic and Oncologic Disease
December 2nd 2000The use of thalidomide (Thalomid) in the treatment of hematologic diseases and in solid tumors as monotherapy or in combination with other agents is an exciting development in cancer therapy. Researchers actively involved in studying the role of thalidomide in cancer treatment were convened at a special investigators’ meeting held this past May in New Orleans. The articles in this supplement are based on the presentations made at this investigators’ meeting.
Radiation Therapy After Mastectomy: Mistaken Assumptions
December 1st 2000I am writing in reference to your “Oncology Rounds” section in the September 2000 issue of Oncology News International (page 18). In the first case, entitled “What further therapy for this woman postmastectomy?” I noted that in the answer given by I. Craig Henderson, MD, there was no specific mention of adjuvant radiation therapy.
Faces Pain Scale Useful in Evaluating Pain in Younger Children
December 1st 2000CALLAHAN, Australia-A new study suggests that the Faces Pain Scale (FPS) is “sensitive and discriminating” for use in evaluating pain in young children, but does not function as a truly linear scale. Children in the study had difficulty discriminating among Faces 3, 4, and 5 and between Faces 5 and 6, said Mark Hunter, PhD, of the Department of Psychology, University of Newcastle.
NIH Funds Two New CAM Cancer Therapy Research Centers
December 1st 2000BETHESDA, Md-Two new research centers funded by the National Institutes of Health will focus on basic and clinical research of complementary and alternative medicine (CAM) cancer therapies. The centers, at Johns Hopkins University and the University of Pennsylvania, will each receive nearly $8 million over 5 years.
Vessel Sealing Tool Effective in Laparoscopic Colon Surgery
December 1st 2000BOSTON-A new electrosurgical tool that seals blood vessels without staples or vascular clips is safe and effective for laparoscopic colon surgery, according to a study reported at the American Society of Colon and Rectal Surgeons (ASCRS) annual meeting.
Allogeneic Stem Cell Transplants: Supportive Care Is Key
December 1st 2000HOUSTON-Supportive care for patients undergoing allogeneic hematopoietic stem cell transplantation presents a series of challenges, from regimen-related toxicity to chronic graft-versus-host disease (GVHD), said Daniel Couriel, MD, assistant professor of blood and marrow transplantation, M.D. Anderson Cancer Center.
‘Eclipse’ Cigarettes Higher in Carcinogens Than ‘Ultralights’
December 1st 2000WASHINGTON-Several health groups have demanded that R.J. Reynolds Co. withdraw its new Eclipse cigarette from test marketing after an analysis showed that the cigarette exposes smokers to greater amounts of carcinogens than two currently available “ultralight” brands. The company has said that Eclipse contains fewer carcinogens than other cigarettes and may reduce the risk of smoking-related cancers.
Study Supports Full Staging Workup for Orbital Lymphoma
December 1st 2000BOSTON-Patients diagnosed with orbital lymphoma should have a complete staging workup before radiation therapy, according to a Rare Cancer Network presentation at the American Society for Therapeutic Radiology and Oncology (ASTRO) annual meeting.
Gap Persists Between Research Results, Application
December 1st 2000WASHINGTON-“Without even waiting for the research of tomorrow, we could save tens or hundreds of thousand of lives if we could apply 100% of what we know now about breast cancer diagnosis and treatment,” said Gabriel Hortobagyi, MD, chairman of Breast Medical Oncology, M.D. Anderson Cancer Center. “There is still a persistent gap between what we have learned and its application into clinical practice, simply because the translation of research into clinical practice is very slow.”
NCI Funds 4-Year Projects at 12 Tobacco Research Centers
December 1st 2000BETHESDA, Md-The National Cancer Institute (NCI) has launched its new antismoking initiative, Research in State and Community Tobacco Control Interventions, by awarding 12 grants totaling $13 million. The money will support the first year of 4-year research projects on local, state, and multistate tobacco prevention and control programs.
Book Review: Progress in Anti-Cancer Chemotherapy, Volume II
December 1st 2000The book Progress in Anti-Cancer Chemotherapy, Volume II is the second of a series of three books edited by Drs. Hortobagyi and Khayat, and published by different publishing houses between 1998 and 1999. Volume II is a collection of
Evidence-Based Medicine Key to Mainstreaming of NOAT
December 1st 2000PHILADELPHIA-The Society for Nutritional Oncology Adjuvant Therapy (NOAT) is an interdisciplinary professional organization that addresses the role of nutrition and metabolism in oncology. Founded in 1994, NOAT is the first organization devoted solely to studying the role of nutrition in cancer (see box).
Improvements in DCIS Pathologic Diagnosis
December 1st 2000CHICAGO-The diagnosis of ductal carcinoma in situ (DCIS) usually is straightforward from a pathologic point of view. However, microinvasion and histologically ambiguous lobular carcinoma in situ (LCIS) lesions may be difficult to distinguish from DCIS, Stuart Schnitt, MD, said at the Second Annual Lynn Sage Breast Cancer Symposium, sponsored by Northwestern University Medical School.
RT After Wide Excision for DCIS Is Debated
December 1st 2000CHICAGO-Results from two published prospective randomized clinical trials of women with ductal carcinoma in situ (DCIS) show that radiotherapy after wide excision reduces local recurrence by 7% to 15%, said Melvin J. Silverstein, MD, who does not believe radiotherapy is suitable for all women with this form of breast disease.
Dr. Hussey Foresees More Physician Competency Reviews
December 1st 2000BOSTON-David H. Hussey, MD, president of the American Society for Therapeutic Radiology and Oncology (ASTRO), predicts that increased assessment of physician competence will have a profound and positive effect on medical training for new and practicing physicians in all medical specialties.
Pharmacology of Antineoplastic Agents in Older Cancer Patients
December 1st 2000People over the age of 65 are a fast-growing segment of the US population, and with the incidence of cancer increasing with age, the challenges of treating older cancer patients are also on the rise. Drs. Lichtman and Skirvin present a comprehensive review of the antineoplastic agents used in elderly cancer patients. They highlight the important factors of chemotherapy pharmacology in elderly cancer patients, with emphasis on the impact of physiologic changes-especially renal clearance-in dosing and toxicity. In addition, descriptions of significant toxicities are provided. The following additional issues should be considered.
Pharmacology of Antineoplastic Agents in Older Cancer Patients
December 1st 2000People over the age of 65 are a fast-growing segment of the US population, and with the incidence of cancer increasing with age, the challenges of treating older cancer patients are also on the rise. Drs. Lichtman and Skirvin present a comprehensive review of the antineoplastic agents used in elderly cancer patients. They highlight the important factors of chemotherapy pharmacology in elderly cancer patients, with emphasis on the impact of physiologic changes-especially renal clearance-in dosing and toxicity. In addition, descriptions of significant toxicities are provided. The following additional issues should be considered.